© Reuters.
Natera, Inc. (NASDAQ:) CEO and President Steven Leonard Chapman engaged in significant stock transactions on March 15, 2024, as disclosed in a recent filing. The transactions included both acquiring and disposing of shares in the medical laboratories services provider.
Chapman exercised options to acquire a total of 68,270 shares of common stock, with prices ranging from $13.01 to $25.46, amounting to approximately $1.32 million. Following these acquisitions, Chapman sold a total of 83,223 shares in multiple transactions. The sales were executed at weighted average prices that varied between $87.9648 and $89.6308, totaling around $7.4 million.
Investors often scrutinize insider transactions for insights into executives’ perspectives on their company’s stock value. In this case, the CEO’s decision to sell a substantial number of shares, especially at prices significantly higher than the acquisition costs, could be of interest to current and potential shareholders.
Chapman’s transactions were conducted under a prearranged 10b5-1 trading plan, a tool allowing insiders to set up a predetermined plan for trading stock at a future date, providing an affirmative defense against accusations of trading on nonpublic information.
Following these transactions, the reporting documents also listed holdings in a trust where Chapman disclaims beneficial ownership except to the extent of his pecuniary interest. The Rosewood Trust, an irrevocable spendthrift trust, holds 50,910 shares for the benefit of Chapman and other discretionary beneficiaries.
Natera, headquartered in Austin, Texas, specializes in genetic testing and diagnostics and has seen its stock price move with the broader market trends and company-specific news.
For investors, these filings provide transparency and can serve as one of many factors considered when evaluating a company’s stock for investment.
InvestingPro Insights
As investors analyze the recent stock transactions by Natera, Inc.’s (NASDAQ:NTRA) CEO, it is also crucial to consider the broader financial metrics and market performance of the company. Natera’s market capitalization stands at a robust $10.81 billion, reflecting investor confidence and the company’s market presence. Despite this, the company’s P/E ratio is currently negative at -24.86, indicating that Natera is not profitable as of the last twelve months ending Q4 2023. This aligns with the InvestingPro Tips that suggest analysts do not expect the company to be profitable this year.
However, Natera has demonstrated a high return over the last year, with a 53.58% one-year price total return, suggesting a strong market performance that could be appealing to growth-focused investors. The company’s recent revenue growth is also notable, with a 31.99% increase in the last twelve months as of Q4 2023, which may signal underlying business strength. Moreover, with a Price / Book ratio of 14.13, the company is trading at a high valuation compared to its book value, which is a point of consideration for value investors.
For those seeking further insights and tips, the InvestingPro Tips highlight that Natera has a strong return over the last month and three months, with price total returns of 27.87% and 51.7%, respectively. Additionally, the company’s liquid assets exceed its short-term obligations, indicating a sound liquidity position. These financial insights, along with a total of 14 additional tips available on InvestingPro, can help investors make more informed decisions. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enriching their investment research with valuable data and analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
